Literature DB >> 21270785

Pharmacogenetics and clopidogrel response in patients undergoing percutaneous coronary interventions.

A L Beitelshees1, R B Horenstein, M R Vesely, M R Mehra, A R Shuldiner.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21270785      PMCID： PMC3235907          DOI： 10.1038/clpt.2010.316

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  28 in total

1.  Clopidogrel with or without omeprazole in coronary artery disease.

Authors:  Deepak L Bhatt; Byron L Cryer; Charles F Contant; Marc Cohen; Angel Lanas; Thomas J Schnitzer; Thomas L Shook; Pablo Lapuerta; Mark A Goldsmith; Loren Laine; Benjamin M Scirica; Sabina A Murphy; Christopher P Cannon
Journal:  N Engl J Med       Date:  2010-10-06       Impact factor: 91.245

2.  CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network.

Authors:  M V Relling; T E Klein
Journal:  Clin Pharmacol Ther       Date:  2011-01-26       Impact factor: 6.875

Review 3.  Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis.

Authors:  J M Siller-Matula; B Jilma; K Schrör; G Christ; K Huber
Journal:  J Thromb Haemost       Date:  2010-12       Impact factor: 5.824

4.  Clopidogrel loading dose adjustment according to platelet reactivity monitoring in patients carrying the 2C19*2 loss of function polymorphism.

Authors:  Laurent Bonello; Sébastien Armero; Omar Ait Mokhtar; Julien Mancini; Philippe Aldebert; Noémie Saut; Nathalie Bonello; Paul Barragan; Stéphane Arques; Marie-Paule Giacomoni; Caroline Bonello-Burignat; Marie-Noelle Bartholomei; Françoise Dignat-George; Laurence Camoin-Jau; Franck Paganelli
Journal:  J Am Coll Cardiol       Date:  2010-08-12       Impact factor: 24.094

5.  Pilot study of the antiplatelet effect of increased clopidogrel maintenance dosing and its relationship to CYP2C19 genotype in patients with high on-treatment reactivity.

Authors:  Colin M Barker; Sarah S Murray; Paul S Teirstein; David E Kandzari; Eric J Topol; Matthew J Price
Journal:  JACC Cardiovasc Interv       Date:  2010-10       Impact factor: 11.195

6.  Prasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial data.

Authors:  M J Sorich; A Vitry; M B Ward; J D Horowitz; R A McKinnon
Journal:  J Thromb Haemost       Date:  2010-05-21       Impact factor: 5.824

7.  Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement.

Authors:  Dirk Sibbing; Werner Koch; Daniela Gebhard; Tibor Schuster; Siegmund Braun; Julia Stegherr; Tanja Morath; Albert Schömig; Nicolas von Beckerath; Adnan Kastrati
Journal:  Circulation       Date:  2010-01-18       Impact factor: 29.690

8.  Pharmacogenetic testing for clopidogrel using the rapid INFINITI analyzer: a dose-escalation study.

Authors:  Patrick Gladding; Harvey White; Jamie Voss; John Ormiston; Jim Stewart; Peter Ruygrok; Badi Bvaldivia; Ruth Baak; Catherine White; Mark Webster
Journal:  JACC Cardiovasc Interv       Date:  2009-11       Impact factor: 11.195

9.  Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.

Authors:  Alan R Shuldiner; Jeffrey R O'Connell; Kevin P Bliden; Amish Gandhi; Kathleen Ryan; Richard B Horenstein; Coleen M Damcott; Ruth Pakyz; Udaya S Tantry; Quince Gibson; Toni I Pollin; Wendy Post; Afshin Parsa; Braxton D Mitchell; Nauder Faraday; William Herzog; Paul A Gurbel
Journal:  JAMA       Date:  2009-08-26       Impact factor: 56.272

10.  Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study.

Authors:  Jean-Philippe Collet; Jean-Sébastien Hulot; Anna Pena; Eric Villard; Jean-Baptiste Esteve; Johanne Silvain; Laurent Payot; Delphine Brugier; Guillaume Cayla; Farzin Beygui; Gilbert Bensimon; Christian Funck-Brentano; Gilles Montalescot
Journal:  Lancet       Date:  2008-12-26       Impact factor: 79.321
View more
  6 in total

Review 1.  Personalized medicine: is it a pharmacogenetic mirage?

Authors:  Rashmi R Shah; Devron R Shah
Journal:  Br J Clin Pharmacol       Date:  2012-10       Impact factor: 4.335

Review 2.  Impact of genetic polymorphisms on platelet function and response to anti platelet drugs.

Authors:  Teresa Strisciuglio; Danilo Franco; Giuseppe Di Gioia; Chiara De Biase; Carmine Morisco; Bruno Trimarco; Emanuele Barbato
Journal:  Cardiovasc Diagn Ther       Date:  2018-10

3.  Multi-ethnic distribution of clinically relevant CYP2C genotypes and haplotypes.

Authors:  S Martis; I Peter; J-S Hulot; R Kornreich; R J Desnick; S A Scott
Journal:  Pharmacogenomics J       Date:  2012-04-10       Impact factor: 3.550

Review 4.  Is There Still a Role for Glycoprotein IIb/IIIa Antagonists in Acute Coronary Syndromes?

Authors:  Loredana Iannetta; Paolo Emilio Puddu; Domenico Cuturello; Angela Saladini; Mariano Pellicano; Michele Schiariti
Journal:  Cardiol Res       Date:  2013-03-08

5.  Prevalence of the CYP2C19*2 (681 G>A), *3 (636 G>A) and *17 (‑806 C>T) alleles among an Iranian population of different ethnicities.

Authors:  Mahshid Dehbozorgi; Behnam Kamalidehghan; Iman Hosseini; Zahra Dehghanfard; Mohammad Hossein Sangtarash; Maryam Firoozi; Fatemeh Ahmadipour; Goh Yong Meng; Massoud Houshmand
Journal:  Mol Med Rep       Date:  2018-01-05       Impact factor: 2.952

6.  Reduced number of cardiovascular events and increased cost-effectiveness by genotype-guided antiplatelet therapy in patients undergoing percutaneous coronary interventions in the Netherlands.

Authors:  B A L M Deiman; P A L Tonino; K Kouhestani; C E M Schrover; V Scharnhorst; L R C Dekker; N H J Pijls
Journal:  Neth Heart J       Date:  2016-10       Impact factor: 2.380
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.